Forgot your password?


To create an account to access your personal
My Account OR Dashboard, click REGISTER below.


New Provider Enrollment

To access on-line enrollment / new provider package, click ENROLL below.




Allen G. Meek, MD
The Department of Radiation Oncology is pleased to announce the availability of stereotactic radiotherapy at its Stony Brook University Hospital site. This is a substantial expansion of our current radiosurgery program and will allow stereotactically directed radiation to be applied to both intracranial and extracranial targets.

For several years the Department of Radiation Oncology has performed stereotactic radiosurgery for the management of benign and malignant intracranial diagnoses, such as acoustic neuroma, primary and secondary malignant brain tumors and meningiomas. Stereotactic radiosurgery is given in a single treatment and utilizes an invasive localizing frame fixed to the patient's skull to provide the stereotactic localization. The radiation is provided by a conventional medical linear accelerator with appropriate accessories for beam collimation.

Stereotactic radiotherapy utilizes a non-invasive stereotactic localizing device, a rigid face mask which allows repeated treatments (fractions) with the identical set up, thus the nomenclature of "radiotherapy" rather than "radiosurgery" which implies a single fraction. With multiple fractions, higher doses of radiation can be administered to the target with greater safety and biologic efficacy. A specialized medical linear accelerator was installed for this procedure which has very fine and accurate aperture definition allowing highly precise radiation therapy. The radiation targets are defined by fused MRI and CT images specifically performed for this procedure. The precision of radiation delivery allows us to place very tight margins around the targets thereby sparing adjacent normal tissues.

To date we have treated over a dozen patients with intracranial benign and malignant lesions on this new unit. The unit has functioned perfectly and we look forward to a substantial expansion of the program. Later this summer, the stereotactic localizing device for extracranial targets will be brought on line. This will allow stereotactic radiotherapy for a variety of diagnoses such as spinal tumors, primary tumors of the prostate, pancreas and liver and metastatic lesions to the liver and adrenal glands. Clinical trials for treatments of these diagnoses are currently being developed. High efficacy and low morbidity are the goals of Department of Radiation Oncology's Stereotactic Radiotherapy Program and the Program should be of considerable benefit to cancer patients on Long Island.

Dr. Meek is professor and chair, department of radiation oncology at the Stony Brook University School of Medicine.
Make An Appointment

Important Note:

The Stony Brook Medicine University Physicians website is primarily an informational and educational resource. It should not be used in place of medical advice and recommendations you receive from your health care provider. If you have, or suspect that you have a medical problem or condition, please seek the advice of your health care provider.

Stony Brook Medicine University Physicians provides marketing advice and consultation to the clinical Faculty associated with the University Faculty Practice Corporations (UFPCs). It does not provide medical care directly or indirectly nor does it oversee, direct, manage or supervise the medical care provided by any of the individual Practices. The individual Practices are responsible for the medical care each Practice provides to its patients. Please note that the Practices listed below are separate University Faculty Practice Corporations (UFPCs).